Biometric Monitoring

Snapshot

What is this Market Category?

Why Now?

• The regulatory lane widened without eliminating the medical-device boundary. FDA’s 2026 General Wellness guidance expressly contemplated non-invasive optical sensing of blood pressure, oxygen saturation, glucose and heart-rate variability as general wellness when the intended use is low-risk and non-clinical. [^7uqywd] [^7uqywd] The same guidance excludes products that diagnose, monitor or manage disease, substitute for an authorized device or prompt clinical action, allowing startups to commercialize longitudinal signals earlier while reserving medical claims for cleared products. ^{[h9l6ih] [h9l6ih]}
• Sensor form factors have crossed from occasional measurement to passive longitudinal monitoring. Optical PPG, ECG electrodes, temperature sensors, accelerometers and electrochemical biosensors now fit in rings, watches, adhesive patches and minimally invasive microneedle arrays; Apple’s hypertension feature, for example, passively analyzes 30 days of optical-sensor data rather than requiring a discrete cuff reading. ^{[7oyxfe] [7oyxfe] [l16kqp] [l16kqp]} Research reviews now treat wearable and implantable biosensors as platforms for continuous real-time monitoring of both biophysical and biochemical signals. [^qq6u8e] [^qq6u8e]
• AI is shifting differentiation from measurement hardware to interpretation. The AI-in-remote-patient-monitoring segment was valued at $1.99 billion in 2024 and is forecast to reach $8.51 billion by 2030, a 27.98% CAGR, reflecting demand for baseline detection, deterioration prediction and personalized coaching rather than raw dashboards. ^{[8i6wlo] [8i6wlo]} Sensor Tower’s 2026 market assessment similarly found competition moving toward companion applications that translate sleep, heart-rate and recovery data into usable health insights. [^g1mvuz] [^g1mvuz]
• Consumer distribution has created a population-scale data layer. IDC reported 611.5 million wearable shipments in 2025 and forecasts approximately 689.7 million units in 2030. [^346t4j] [^346t4j] Google reported that more than 19 million Fitbit users had enrolled in its irregular-heart-rhythm notification feature, demonstrating how a consumer platform can distribute an opt-in biometric-screening capability at clinical-scale volumes. [^26glkp] [^26glkp]
• Care is moving outside the hospital. Grand View Research attributes RPM expansion to chronic-disease prevalence, aging populations and demand for continuous observation outside traditional care settings; it forecasts the market from $26.0 billion in 2025 to $110.7 billion in 2033. ^{[hia81p] [hia81p] [omu3r0] [omu3r0]} Biofourmis now markets technology-enabled care in 25 U.S. states and reports partnerships with more than 50 health systems and payers, illustrating buyer demand for sensing plus clinical operations rather than standalone hardware. [^1z8cy1] [^1z8cy1]

What's Happening?

CAGR and TAM

• Clinical wearable monitoring: Grand View Research’s Clinical Wearable Monitoring Devices Market, 2026–2033 values the global market at $22.0 billion in 2025, $24.8 billion in 2026 and $65.2 billion in 2033, implying a 14.8% CAGR. [^smqev7] [^smqev7] Its revenue model segments the market by product, connectivity, application, end user and geography, with historical and forecast analysis from 2021 through 2033. [^k9ombu] [^k9ombu]
• Wearable medical devices: Grand View’s broader Wearable Medical Device Market, 2026–2033 estimates $60.8 billion in 2025, $68.8 billion in 2026 and $182.9 billion in 2033, a 15.0% CAGR. [^n3u6g5] [^n3u6g5] Mordor Intelligence uses a narrower scope and produces a lower estimate—$48.26 billion in 2025, $55.7 billion in 2026 and $114.09 billion in 2031, or 15.41% CAGR—showing that inclusion of therapeutic wearables, consumer products and services materially changes the TAM. [^m84ubu] [^m84ubu]
• Remote patient monitoring and enabling sensors: Grand View forecasts RPM systems from $26.0 billion in 2025 to $110.7 billion in 2033 at 20.0% CAGR, while MarketsandMarkets forecasts the much broader biosensor market from $34.5 billion in 2025 to $54.37 billion in 2030 at 9.5% CAGR. ^{[hia81p] [hia81p]} [^wdjq46] [^wdjq46] The figures should not be added: RPM includes service and platform revenue, while biosensors include non-wearable and non-health applications.

Category creation events

• Apple’s hypertension notification converted a consumer optical sensor into population-scale longitudinal screening. The FDA cleared the software in September 2025; it analyzes opportunistically collected Apple Watch PPG over 30-day periods and notifies users of patterns suggestive of hypertension without providing a cuff-equivalent blood-pressure reading. ^{[7oyxfe] [7oyxfe] [l16kqp] [l16kqp]}
• Dexcom’s $75 million strategic investment in Oura made cross-modal monitoring a reference architecture. The companies connected continuous glucose data with Oura’s sleep, activity, stress and vital-sign signals and agreed to integrate, cross-sell and co-market their products. [^k41oa3] [^k41oa3] [^owjs58] [^owjs58] This helped move “biometric monitoring” from one-device/one-signal products toward multimodal personal-health platforms.
• The FDA’s January 2026 wellness guidance crystallized the category dispute. The agency said that a non-invasive device can output clinically familiar physiological parameters and still remain a wellness product when claims are restricted, outputs are validated and the product does not guide medical management. [^nxqyh2] [^nxqyh2] [^5ax85x] [^5ax85x] Critics argue that the guidance leaves validation thresholds and informational-safety obligations insufficiently defined. [^or7qas] [^or7qas] [^nhc0yd] [^nhc0yd]

Capital concentration

• Capital has concentrated in two mature consumer platforms. Oura raised more than $900 million at an approximately $11 billion valuation in October 2025, while WHOOP raised $575 million at a $10.1 billion valuation in March 2026; together those rounds placed approximately $1.475 billion into two subscription-oriented biometric platforms. ^{[56u88m] [56u88m]} [^0ugbur] [^0ugbur]
• The Series C–D layer is funding category-specific wedges. Biolinq closed a $100 million Series C led by Alpha Wave Ventures for an autonomous intradermal glucose sensor; Eight Sleep raised $100 million for biometric sleep and thermal-control products; and Ultrahuman raised $70 million with Qualcomm Ventures and other strategic investors to expand smart-ring sensing and on-device software. [^9tf67r] [^9tf67r] [^lhw48s] [^lhw48s] [^e9kygu] [^e9kygu]
• Series A–B capital is moving toward new analytes and sensing sites. Sava raised $19 million for a minimally invasive multi-molecule sensor, Epicore expanded its sweat-sensing Series B to $32 million, Nix raised a $10 million Series A for hydration intelligence and Xsensio raised $7 million for a “Lab-on-Skin” platform targeting metabolites, proteins and hormones. [^55f5ag] [^55f5ag] [^eohpm7] [^eohpm7] [^o6wx7s] [^o6wx7s] [^v08pz2] [^v08pz2]

Market Incumbents

• Apple — Apple Watch combines mass-market distribution with ECG, heart-rate, temperature, blood-oxygen and FDA-cleared hypertension-notification capabilities. [^9y2ax7] [^9y2ax7] ^{[7oyxfe] [7oyxfe]}
• Alphabet / Google Fitbit — Fitbit and Pixel Watch provide continuous activity, sleep, heart-rate and rhythm monitoring, with more than 19 million users enrolled in Fitbit’s irregular-rhythm notification feature. [^26glkp] [^26glkp]
• Samsung Electronics — Galaxy Watch and Galaxy Ring combine PPG, electrical-heart-signal, temperature, movement and bioimpedance sensing within Samsung Health. [^730glr] [^730glr]
• Dexcom — The leading glucose-biosensing specialist serves approximately 3.5 million customers and has expanded beyond prescription diabetes management with the over-the-counter Stelo sensor. [^bgjcv1] [^bgjcv1] [^7s2zao] [^7s2zao]
• Philips — Philips supplies hospital, ambulatory and enterprise patient-monitoring systems as part of a healthcare business with €17.8 billion in 2025 sales and operations in more than 100 countries. [^48gb1k] [^48gb1k] [^fvs2cb] [^fvs2cb]
• Masimo — Masimo’s SET pulse-oximetry and patient-monitoring technology is used to monitor more than 200 million patients annually and is the primary pulse-oximetry technology at the top ten U.S. hospitals in its cited ranking. [^b94vdj] [^b94vdj]
• Oura — Oura has made the smart ring a mainstream sleep, recovery and preventive-health form factor, selling more than 5.5 million devices by October 2025 and projecting more than $1 billion in 2025 revenue. ^{[56u88m] [56u88m]}
• WHOOP — WHOOP operates a screenless, subscription-first biometric band centered on strain, sleep and recovery, with more than 2.5 million members and a $1.1 billion bookings run rate exiting 2025. ^{[l6jtir] [l6jtir]}

Incumbent cards

Apple

Dexcom

Oura

Market Challengers

• Ultrahuman — A subscription-free smart-ring challenger combining sleep, HRV, temperature, movement and recovery monitoring with ambitions for on-device software and AI. [^e9kygu] [^e9kygu] [^yz39s7] [^yz39s7]
• Eight Sleep — Uses a sensor-rich mattress cover to monitor sleep and adjust bed temperature, reporting more than $500 million in cumulative Pod sales and over one billion hours of sleep data. [^lhw48s] [^lhw48s]
• Biofourmis — Combines biosensor data, predictive analytics and clinical operations for hospital-at-home, post-acute and chronic care across more than 50 health-system and payer partners. [^1z8cy1] [^1z8cy1]
• Biolinq — Develops a minimally invasive intradermal glucose patch with autonomous sensing and on-device visual feedback, backed by a $100 million Series C. [^9tf67r] [^9tf67r] [^0oonnt] [^0oonnt]
• AliveCor — Provides FDA-cleared personal ECG hardware, AI interpretation and remote-cardiology subscriptions, with more than two million customers and 160 million ECGs recorded by its 2022 Series F. [^h3n58o] [^h3n58o]
• Hilo — Formerly Aktiia, Hilo offers a cuffless optical blood-pressure bracelet and analytics platform, with more than 120,000 devices sold and over $100 million raised. [^ke586k] [^ke586k]

Challenger cards

Ultrahuman

Biofourmis

Biolinq

Market Innovators

• Sava Technologies — Develops a minimally invasive, multi-molecule microsensor intended to monitor glucose and eventually lactate, ketones, cortisol and other analytes in real time. [^q5rg8s] [^q5rg8s]
• Epicore Biosystems — Builds sweat-sensing patches and cloud analytics for athletes, industrial workers, military users and clinical research. [^7ab22e] [^7ab22e] [^la5byw] [^la5byw]
• Nix Biosensors — Measures fluid and electrolyte loss through a bicep-mounted sweat sensor and is converting its dataset into licensable hydration algorithms. [^p5vxid] [^p5vxid] [^r5pkru] [^r5pkru]
• Xsensio — Its Lab-on-Skin chip targets continuous measurement of metabolites, ions, proteins and hormones using multiple miniaturized sensors. [^v08pz2] [^v08pz2]
• Levels — Combines optional continuous glucose monitors, blood testing, nutrition, sleep and exercise data into a consumer metabolic-health application used by more than 60,000 members. [^xihgl3] [^xihgl3]
• Incora Health — Develops smart earrings for women’s health, using the earlobe as a sensing site for temperature, heart rate, oxygen saturation and respiratory signals. [^54yjii] [^54yjii] [^ukwps9] [^ukwps9]

Innovator cards

Sava Technologies

Epicore Biosystems

Nix Biosensors

Industry Coverage and Market Data

Market Reports

• Clinical Wearable Monitoring Devices Market, 2026–2033 — Grand View Research — Global revenue forecast segmented by product, connectivity, application, end user and region; estimates $22.0 billion in 2025 and $65.2 billion in 2033, a 14.8% CAGR. [^smqev7] [^smqev7] [^k9ombu] [^k9ombu]
• Remote Patient Monitoring System Market, 2026–2033 — Grand View Research — Global top-down revenue forecast covering devices and monitoring systems; estimates $26.0 billion in 2025 and $110.7 billion in 2033 at 20.0% CAGR. ^{[hia81p] [hia81p]}
• Wearable Medical Device Market, 2026–2033 — Grand View Research — Segments diagnostic and therapeutic devices by site, application, grade, channel and geography; forecasts $60.8 billion in 2025 to $182.9 billion in 2033. [^n3u6g5] [^n3u6g5]
• Wearable Medical Devices Market, 2026–2031 — Mordor Intelligence — Uses a narrower wearable-medical-device scope than Grand View and estimates $55.7 billion in 2026, rising to $114.09 billion by 2031 at 15.41% CAGR. [^m84ubu] [^m84ubu]
• Biosensors Market by Type, Product, Technology, Application and Region, 2025–2030 — MarketsandMarkets — Bottom-up and company-revenue-oriented segmentation across wearable and non-wearable electrochemical, optical, piezoelectric, thermal and nanomechanical sensors; forecasts $34.5 billion in 2025 to $54.37 billion in 2030. [^wdjq46] [^wdjq46] [^tw0xbg] [^tw0xbg]
• Worldwide Wearable Device Tracker, 2026 — IDC — Shipment-based rather than revenue-based market measurement; reports 611.5 million units in 2025 and forecasts 689.7 million in 2030. [^346t4j] [^346t4j]

Industry Articles

• A guide to consumer-grade wearables in cardiovascular clinical care and population health for non-experts — npj Cardiovascular Health , Jamieson, Chico, Jones et al. — Reviews sensors, accuracy, clinical workflow and population-health use; reports that heart-rate measurements at rest commonly show mean absolute errors around two beats per minute. [^3qwlz3] [^3qwlz3]
• Can consumer wearables support outpatient health monitoring? — PLOS Digital Health — A preregistered umbrella review finding heterogeneous performance across biometrics and populations and limited evidence of clinical utility. [^lwu0vx] [^lwu0vx]
• Wearables research for continuous monitoring of patient outcomes: A scoping review — PLOS Digital Health , Lodewyk, Wiebe, Dennett et al. — Maps the continuous-monitoring evidence base and concludes that evidence of clinical effectiveness remains limited. [^5vyo3r] [^5vyo3r]
• Unaddressed implications of the FDA’s 2026 guidance on wellness devices — Nature Biomedical Engineering — Critiques the guidance’s validation standards, safety framework and distinction between wellness and medical use. [^or7qas] [^or7qas]
• Wearable Makers Eye Healthcare, New Innovations — Athletech News — Tracks WHOOP, Oura, Apple and Garmin as they add blood pressure, ECG, lab and connected-care features; highlights WHOOP’s dispute with FDA over whether Blood Pressure Insights required authorization. [^nh5g27] [^nh5g27]
• When Does a Fitness Tracker Become a Medical Device? — Duke Pratt School of Engineering — Explains how the 2026 FDA guidance makes claims and intended use, rather than the measured parameter alone, central to classification. [^zzmw01] [^zzmw01]

Financial News Sources

• WHOOP Raises $575 Million at a $10 Billion Valuation on Its Way to an IPO — Bloomberg — Reports the $575 million Series G, $10.1 billion valuation, 2.5 million members, positive 2025 cash flow and 103% subscription growth. [^0ugbur] [^0ugbur]
• Oura Ring maker to be valued at around $11 billion with latest raise — Reuters — Reports Oura’s planned $875 million-plus financing and the doubling of its valuation from $5.2 billion. [^t3xtif] [^t3xtif]
• Oura reaches $11 billion valuation with new $900 million funding round — CNBC — Confirms the completed round and Oura’s reported 2024 revenue above $500 million and 2025 $1 billion sales target. ^{[icf5gz] [icf5gz]}
• Eight Sleep raises $100M to expand its AI-powered sleep tech — TechCrunch — Reports approximately $260 million in cumulative funding, more than $500 million in Pod sales and over one billion hours of sleep data. [^lhw48s] [^lhw48s]
• Biofourmis books $300M to bring health home — Axios — Covers the General Atlantic-led Series D, near-$1.3 billion valuation and expansion from post-acute monitoring into chronic care. [^4ffc1d] [^4ffc1d]
• Nix raises $10M to license its hydration data to health apps — Dealroom — Reports Nix’s Series A and its move from a proprietary sensor toward licensable hydration intelligence. [^9up2u8] [^9up2u8]

Frontier and Open Questions

• Will regulators continue classifying the same physiological output differently according to intended use, or impose baseline validation standards on all clinically analogous measurements? The FDA currently permits some non-invasive blood-pressure, glucose and oxygen outputs to remain under general-wellness policy, but academic critics argue that “validated” is insufficiently defined. [^5ax85x] [^5ax85x] [^nhc0yd] [^nhc0yd] Incumbents Apple, Google and Samsung—and challenger WHOOP—will drive resolution through product claims and enforcement disputes.
• Can consumer wearables demonstrate clinical utility rather than merely measurement correlation? Reviews find relatively strong resting heart-rate performance but heterogeneous accuracy across other signals and limited evidence that monitoring improves outcomes. [^3qwlz3] [^3qwlz3] [^lwu0vx] [^lwu0vx] Clinical incumbents Dexcom, Philips and Masimo, together with Biofourmis and AliveCor, are best positioned to connect signals to reimbursable interventions.
• Does the category expand from optical vital signs into continuous molecular monitoring? Sava, Biolinq, Epicore and Xsensio are developing platforms for glucose, electrolytes, metabolites, proteins and hormones, but durability, calibration and regulatory validation remain major commercialization gates. [^9tf67r] [^9tf67r] [^55f5ag] [^55f5ag] [^v08pz2] [^v08pz2] Innovators are most likely to resolve this frontier, while Dexcom could consolidate successful platforms.
• Will the winning interface be a watch, ring, patch, hearable, garment or ambient surface? Oura and Ultrahuman favor fingers, Apple and WHOOP favor wrists, Biolinq and Epicore use patches, Incora uses the ear and Eight Sleep embeds sensing in the bed. [^sd6rig] [^sd6rig] [^yz39s7] [^yz39s7] [^0oonnt] [^0oonnt] [^54yjii] [^54yjii] [^lhw48s] [^lhw48s] Challengers and innovators will test whether better signal quality and adherence outweigh the distribution advantages of incumbents.
• Who owns the interpretation layer when measurements flow across devices? Dexcom–Oura integration, Google’s unified Health API and Garmin’s enterprise SDKs point toward biometric data moving into cross-device platforms rather than staying in a single hardware application. [^k41oa3] [^k41oa3] [^mz4r8z] [^mz4r8z] [^xnb1ek] [^xnb1ek] Big-tech incumbents own the operating-system gateways, while Oura, WHOOP and Ultrahuman are building vertically integrated interpretation and subscription layers.
• Can continuous monitoring avoid widening demographic bias? FDA has specifically highlighted skin pigmentation as a source of pulse-oximeter error, and research has found higher optical-estimation errors under some dark-skin conditions. ^{[958s58] [958s58]} [^ayk1n5] [^ayk1n5] Masimo, Apple, Samsung and clinical-grade innovators will need representative validation datasets and transparent performance reporting to resolve the issue.

Adjacent Concepts and Categories

• Remote Patient Monitoring — The care-delivery and reimbursement layer through which biometric data reaches clinicians.
• Digital Biomarkers — Algorithmically derived indicators of health state calculated from longitudinal sensor signals.
• Wearable Medical Devices — The regulated hardware category overlapping clinical-grade biometric monitoring.
• Continuous Glucose Monitoring — The most commercially mature form of continuous biochemical sensing.
• Hospital at Home — Acute-care model that depends on reliable continuous or high-frequency vital-sign monitoring.
• Preventive Health Platforms — Consumer and employer products using biometrics to identify risk before a formal diagnosis.
• General Wellness Devices — The FDA classification boundary for low-risk products that avoid diagnostic or treatment claims.
• Multimodal Biosensing — Fusion of optical, electrical, thermal, motion and biochemical signals to improve interpretation.

Sources